Cargando…

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Background: Fingolimod (Gilenya®) is approved for adult and pediatric patients with highly active relapsing–remitting multiple sclerosis (RRMS). Objectives: The objective was to describe the effectiveness of fingolimod in young adults compared to older patients in clinical practice. Methods: PANGAEA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ziemssen, Tjalf, Albrecht, Holger, Haas, Judith, Klotz, Luisa, Lang, Michael, Lassek, Christoph, Schmidt, Stephan, Ettle, Benjamin, Schulze-Topphoff, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982917/ https://www.ncbi.nlm.nih.gov/pubmed/33763018 http://dx.doi.org/10.3389/fneur.2021.637107

Ejemplares similares

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes
por: Limmroth, Volker, et al.
Publicado: (2020)

Electrocardiographic assessments and cardiac events after fingolimod first dose – a comprehensive monitoring study
por: Limmroth, Volker, et al.
Publicado: (2017)

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration
por: Sehr, Tony, et al.
Publicado: (2020)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System—A Review
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Why Cognitive–Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice
por: Beste, Christian, et al.
Publicado: (2020)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease
por: Thomas, Katja, et al.
Publicado: (2014)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
por: Feng, Jenny, et al.
Publicado: (2019)

IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study
por: Lu, Zhengjuan, et al.
Publicado: (2020)

Spectral Analysis of Heart Rate Variability: Time Window Matters
por: Li, Kai, et al.
Publicado: (2019)

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
por: Ziemssen, Tjalf, et al.
Publicado: (2015)

Editorial: Cognitive Disorders in Neuroimmunological Diseases
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2023)

Data Collection in Multiple Sclerosis: The MSDS Approach
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Should We Use Clinical Tools to Identify Disease Progression?
por: Inojosa, Hernan, et al.
Publicado: (2021)

Diagnosis and Management of Fingolimod-Associated Macular Edema
por: Wang, Chunjiang, et al.
Publicado: (2022)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL
por: Alsop, Jonathan, et al.
Publicado: (2017)

Single-Cell Transcriptome Profiling Unravels Distinct Peripheral Blood Immune Cell Signatures of RRMS and MOG Antibody-Associated Disease
por: Liu, Ju, et al.
Publicado: (2022)

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry
por: Braune, Stefan, et al.
Publicado: (2021)

Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
por: Schriefer, Dirk, et al.
Publicado: (2020)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Balance Testing in Multiple Sclerosis—Improving Neurological Assessment With Static Posturography?
por: Inojosa, Hernan, et al.
Publicado: (2020)

The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2022)

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study
por: Weber, Martin S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_10t6r0atnpi3k90997g58tb11a